ASPIRO: A PHASE 1/2, RANDOMIZED, OPEN-LABEL, ASCENDING-DOSE, DELAYED-TREATMENT CONCURRENT CONTROL CLINICAL STUDY TO EVALUATE THE SAFETY AND PRELIMINARY EFFICACY OF AT132, AN AAV8-DELIVERED GENE THERAPY IN X-LINKED MYOTUBULAR MYOPATHY (XLMTM) PATIENTS
- Registry ID
- ATX-MTM-002
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE1
- Study type
- INTERVENTIONAL
- Sponsor
- ASTELLAS GENE THERAPIES, INC.
- Start date
- 2024-06-05
- Last update
- 2017-10-20
Conditions
- X-LINKED MYOTUBULAR MYOPATHY
View on source registry